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1. Introduction
Helicobacter pylori (H. pylori) was first observed over 100 years ago yet its association with
clinical diseases was not fully understanding until 1982 when Marshall and Warren identified
and subsequently cultured the gastric bacterium. At their first attempt to culture the bacteria
was not successful. Colonies finally grew when they accidentally left some culture plates over
the Easter holiday. Dr. Barry Marshall subsequently inoculated himself with culture broth
containing more than 1 billion organism to prove that this bacterium would cause peptic ulcers
supporting Koch’s postulate. He developed acute gastritis 1 week after the inoculation. H.
pylori is a microaerophilic, spiral shaped, gram negative bacterium measuring about 3.5
microns in length and 0.5 microns in width. In vitro, this bacterium is a gradually growing
organism that can be cultured on blood agar incubated at 37ºC in a microaerophilic condition
(5% oxygen) for 4-7 days. The colony of this bacteria is tiny, uniformly sized and translucence
(fig 2A).
H. pylori is a Gram-negative, spiral shaped, bacterium about 3.5 microns long and 0.5 microns
wide. (fig 2B). This bacterium uses its 2-7 unipolar flagella to escape the harsh luminal acidity
by burrowing into the mucus layer that covers the gastric mucosa and so reside in close
proximity to the more neutral pH of the epithelial cell surface of the gastric mucosa. It can
convert from a highly motile, helical (spiral) shape to a more dormant coccoidal form, perhaps
a survival benefit depending upon its local environment. Being microaerophilic, H. pylori
requires oxygen. H. pylori is biochemically characterized as positive for catalase, oxidase, and
urease. The urease enzyme, which has been located on the surface of the bacteria, is important
and likely to be vital for bacterial survival and colonization in the highly acidity milieu of the
stomach. Urease breaks down the luminal urea normally produced by the gastric mucosa,
yielding carbon dioxide and ammonia.
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Figure 1. or 14C-urea is hydrolyzed by the H pylori urease enzyme and can be detected by CO2 in breath samples
 (A) (B) 
Figure 2. A) H. pylori colonies; (B). H. pylori detected by gram stain
Ammonia then accepts a proton (H+), lessening the nearby acidity and forming protective
surroundings that allow its survival. Furthermore, urease activity is clinically relevance in the
form of several tests to diagnose infection such as rapid urease test and urea breath test. [1-4]
The ammonia produced however is toxic to the epithelium, and aided by other products like
proteases, vacuolating cytotoxin A (associated with cytotoxin-associated gene A ), and certain
phospholipases damages the mucosa. H. pylori infection also increases gastric acid secretion
(suppressing somatostatin to allow increased gastrin), down regulates mucosal defense
mechanisms and elicits an inflammatory response.
H. pylori infects the gastric mucosa in 20-80 % of humans throughout the world, making it a
very common bacterial infection. In developing countries, the infection tends to be acquired
via the fecal-oral or oral-oral route during childhood and subsequently persists through
adulthood. In developed countries, childhood infection is no longer common (rare under 10
years of age) though prevalence does increase during adulthood (>50% if over 50 years); the
latter cohort likely acquired H. pylori during childhood. This bacteria is the major pathologic
agent in the development of gastritis, gastric ulcer, duodenal ulcer, MALT lymphoma and
gastric cancer. The International Agency for Research into Cancer has classified H. pylori as a
class 1 carcinogen which is in the same class as cigarette smoke. [1-3]
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Functional dyspepsia (FD) is one of the most common causes of dyspeptic symptoms. FD
is recognized as heterogeneous group of symptoms located in the center of upper abdo‐
men. The prevalence of dyspepsia is variable in different populations and environmental
factors.  In 2006 the Rome III  provides the diagnostic criteria,  which are included one or
more of the following [5, 6]




The FD patient must not have any evidence of structural disease to explain the dyspeptic
symptoms. Symptom onset should occur at least 6 months prior to diagnosis while the criteria
must be fulfilled for the last 3 months. FD also can be divided into two major syndromes: the
postprandial distress syndrome and the epigastric pain syndrome. The postprandial distress
syndrome type of FD constitutes bothersome postprandial fullness and early satiation,
occurring after meal and at least several times per week. Upper abdominal bloating or
postprandial nausea or excessive belching might be present. In contrast, the epigastric pain
syndrome type of FD mostly suffers with intermittent epigastric pain or burning at least once
a week. The pain should not refer to other abdominal or chest regions, and should not be
relieved by defecation of passage of flatus. [5]
2. Epidemiology of H. pylori infection and FD
H. pylori is a global bacterial infection. Its prevalence varies greatly from 10-80% between
countries, being quite elevated in developing countries in Asia, Africa, and South America but
rather low in North America and Western Europe. In developed countries, approximately 20%
of the population under the age of 40 years and 50% of those over the age of 60 years carry the
infection. [6]
The prevalence of H. pylori infection also varies depending on age, socioeconomic status,
sanitation and ethnic group [4, 7-9]. Typically, the infection is acquired in childhood before
the age of 10 and the rate of acquisition is related inversely to household hygiene and the
general levels of sanitation; wherever sanitation and standards of living have improved, the
incidence of transmission has declined. The low prevalence in middle and upper socioeco‐
nomic populations in Western Europe and North America reflect better sanitation and quality
of living. In the United States, the prevalence rate is approximately 50% in African Americans,
60% in Mexican Americans, and 26% in whites. [4] In developing countries, the prevalence
among adult people is between 50-80%.
H. pylori infection may be evident in 20-60% of patients with functional dyspepsia, but the
clinical  relevance  in  most  instances  is  confounded by the  background frequency of  this
bacteria in the general population. A large scale nationwide community-based endoscopic
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survey of 2,488 adult subjects identified an overall H. pylori infection at 40.2% that was no
different  in  dyspeptic  subjects  compared to  asymptomatic  persons.  Differences  amongst
geographic  regions  likely  related to  differences  in  socioeconomic  status  and community
hygiene during childhood period. [8] The frequency of functional dyspepsia is common in
Asia,  varying  between  8-23% in  most  reported  studies.  [10]  In  fact,  given  the  common
frequency of H. pylori infection and challenges in obtaining endoscopy to eliminate organic
causes of dyspepsia, it is difficult to discern the extent this microorganism is the basis for
dyspepsia in Asia. [10, 11]
There are many FD patients in Asian as well as Western countries. The reported prevalence of
H. pylori infection in patients with FD varies from 39% to 87%. [14] Several epidemiological
studies have shown that H. pylori infection occurs more frequently in FD than in matched
control populations. A meta-analysis published in 1999 reported a summary odds ratio for H.
pylori infection in FD of 1.6 (95% CI, 1.4 to 1.8). [15]
3. Pathogenesis of functional dyspepsia associated with H. pylori infection
The pathophysiological disturbances generally responsible for the dyspepsia focus on
hyperacidity, impaired gastric accommodation (the “stiff fundus”) and delayed gastric
emptying. FD patients who are infected with H. pylori have higher stimulated gastric acid
secretion than H. pylori-negative healthy volunteers. [16] Impaired accommodation to a meal
may be common in functional dyspepsia and early satiety, but is not particularly associated
with H. pylori positivity or delayed gastric emptying. There is no constituent disturbance of
sensory or motor function yet reported in H. pylori-infected persons. Another factor possibly
responsible for the dyspepsia associated with H. pylori infection is the gut hormone, ghrelin.
Secreted from oxyntic cells, ghrelin normally stimulates gastric motility and food intake.
Patients with H. pylori may have reduction in ghrelin secretion that might lead to impaired
gastric emptying and symptoms of postprandial dyspepsia.
Recent study demonstrated that metronidazole resistant strains of H. pylori infection were
significantly higher in PDS than those of EPS patients. This study also indicated more specific
of cagA genotype that presence of cagA 2a gene of H. pylori infection was significantly higher
in metronidazole resistant than those of metronidazole sensitive strains especially in EPS
patients. This finding might be helpful to identify metronidazole resistant by using cagA
genotype in dyspeptic patients. [17]
CagA is a highly immunogenic protein encoded by the cagA gene, located at end of the cag
pathogenicity island (PAI). Infection with cagA-positive strains was associated with a greater
inflammatory response and an increased risk of adverse clinical outcomes than with cagA-
negative strains. [7, 18-20] Taneike et al recently reported that the metronidazole resistant rate
in cagA negative group was significantly higher than in cagA positive group and suggested
that absence of cagA might be a risk factor in development of metronidazole resistance. [21]
Unlike many countries such as European countries and United State of America, nearly all of
H. pylori strains in Thailand possess cagA-positive strains. [16] These different results might be
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explained by variation in cagA between the Asian- and Western-types. CagA genotype can be
divided into cagA 1a and 2a [17] and cagA 1a strain of H. pylori demonstrated more virulence
and associated with more gastric inflammation due to activation of proinflammatory cytokines
such as increased production of IL-1β and IL-8 in the gastric mucosa. [21] Previous meta-
analysis study reported that cagA-positive strain increases the likelihood of successful
eradication. [22] The mechanism for the effect of cagA on eradication outcome might be
explained by the presence of cagA induces secretion of inflammatory cytokine in gastric
epithelial cells and increased gastric inflammatory response. [22] Consequently, the increase
blood flow may help in the diffusion of antibiotics. [23] Another possibility might be explained
by the density of H. pylori in gastric mucosa which has been reported to be higher in cagA-
positive strains than cagA-negative strains, thus cagA-positive strains might be proliferative
faster than cagA-negative strains. [24, 25] As antibiotics are more active on rapidly growing
bacteria, cagA-positive strains would be more susceptible to antibiotic activity [23].
The effect of H. pylori eradication on dyspeptic symptoms in FD patients has revealed incon‐
clusive results in several studies, both in developed countries and in Asia. [26, 27, 28, 29]
Dyspeptic patients who are infected with H. pylori often have functional dyspepsia rather than
peptic ulcer disease, yet the outcome of eradicating H. pylori infection may be suboptimal in
FD compared with that for established duodenal ulcer disease. [30] Nevertheless, at a popu‐
lation level, a Cochrane systemic review indicated that there was a 10% relative risk reduction
of persistent symptoms in the H. pylori-eradication group compared to placebo; the number
needed to treat to cure one case of dyspepsia was 14. [31] A recent meta-analysis of the Chinese
literature showed that dyspepsia symptoms in FD improved after H. pylori eradication with
an odds ratio of 3.61, suggesting that this infection might have a greater role in Asian than in
Western countries. [32] Thus, H. pylori eradication overall does improve dyspepsia, particu‐
larly in regions with high prevalence.
4. H. pylori diagnostic tests in FD
Tests to diagnosis H pylori infection are divided into those that are invasive requiring endos‐
copy versus those that are noninvasive, not requiring endoscopy. The choice of test depends
on issues such as cost (variable in each country), availability, clinical situation, prevalence of
infection, pretest probability of infection, and presence of confounding factors (eg, the use of
PPI and antibiotics) that may influence test results.
a. Noninvasive tests for H. pylori
The noninvasive tests available in clinical practice include serologic tests, urea breath tests,
and stool antigen tests. The choice of test is important in terms of validity
1. Serological tests
IgM and IgA antibody tests have not proven to be useful clinically, whereas anti–H pylori IgG
has a better result. anti–H pylori IgG usually can be detected by 3-4 weeks after infection. The
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three mains methods of commercial kits are ELISA ($90–$95/correct diagnosis),, immunochro‐
matography, and Western blotting.
Most serologic tests carries a high sensitivity (~90 to 100%), but variable specificity (under
85-90%). Their positive and negative predicative values depend upon the background
prevalence of H. pylori infection in the population at risk. In areas where infection is common,
a negative test is likely to be a false negative. Conversely, a positive test amongst those in whom
H pylori is infrequent is more likely to be a false positive. In developed countries with low
prevalence of H. pylori infection (<20%), for example, a positive serological test signals active
infection only about half the time. Hence, serology should be validated locally. Further,
antibody tests can remain positive for years after H pylori eradication and have limited value
to confirm eradication of H pylori infection4.
2. Urea breath test (UBT)
The urea breath test provides a reliable noninvasive method for H pylori detection with
sensitivity and specificity of 88-95% and 95%-100% respectively. [33] Urea breath testing is not
only sensitive and specific but has an important advantage to confirm H pylori eradication.
Following ingestion of 13C- or 14C-urea, H pylori-produced urease enzyme that is resident in
the stomach hydrolyzes this labeled urea to 14CO2 or 13CO2, which can be detected in breath
samples [34] (fig. 1). The nonradioactive13C (a stable label) test and the radioactive 14C test have
received US Food and Drug Administration (FDA) approval for H pylori diagnosis. The dose
of radiation in the 14C-urea test however is not approved for use in children and pregnant
women [4].
3. Fecal H. pylori detection
H. pylori in the stomach also appears in the stool, allowing the development of fecal assays: H
pylori culture, DNA detected by polymerase chain reaction (PCR), or H pylori antigen testing.
Only stool antigen has proven to be clinical useful with sensitivities and specificities of more
than 90%. Stool antigen assay is advantageous to confirm eradication. To avoid false negative
results, it is generally recommended that post-treatment testing with the UBT, histology, stool
antigen test or culture be delayed for 4 weeks and the patients should discontinue proton pump
inhibitors (PPI) and antibiotic such as amoxicillin, clarithromycin and quinolone groups to
ensure that any remaining organisms can repopulate the stomach [4].
b. Invasive tests
Invasive testing which requires endoscopy should be limited to patients who require endos‐
copy for diagnostic or therapeutic evaluation. Invasive tests available in clinical practice
include: gastric biopsies for culture (fig. 2A), gram stain (fig. 2B), histology (fig. 3A), or rapid
urease testing (fig. 3B). Rapid urease test such as CLO test plus upper GI endoscopy usually
cost between 276-502 (average 389) US dollars. H pylori culture is the absolute gold standard
to diagnose H. pylori but culture generally is not available in most hospitals. Good quality
laboratories are capable to culture H. pylori from gastric biopsies in more than 80% of instances
and also offer susceptibility testing such as E-test.
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Figure 3. A.) H pylori detected by histology; (B.) H pylori detected by rapid urease test
Histological examination has an advantage over other diagnostic tests by providing morpho‐
logical information such as severity of gastritis, and evidence for dysplasia. The accuracy of
histological examination however may be variable due to density of H. pylori and sampling
error, and is dependent upon histopathogical interpretation. The accuracy of histological
diagnosis of H pylori infection can be improved by adequate biopsies from the antrum and
body and by special staining such as a silver staining and the Diff-Quik stain [35].
Rapid urease tests contain a solution or gel with urea and a pH indicator reagent. The presence
of urease from H pylori results in hydrolysis of neutral urea to alkaline ammonia, which is then
visualized by a change in color of the pH indicator. The rapid urease test has a high sensitivity
(95%) and specificity (95%), [36] making it an excellent primary diagnostic test.
Any concomitant use of antibiotics or PPI however will reduces bacterial load, and may lead
to false negative tests such as rapid urease tests, urea breath test and histology. [4]
4. Test-and-Treat Strategy for H. pylori
Proposed strategies based on the noninvasive diagnosis of H. pylori infection so-called ‘‘test-
and-treat’’ strategy. This strategy has been proposed for clinical practice in developed
countries which has low prevalence of H. pylori infection. Test-and-treat is based on the test
of the presence of H. pylori and its subsequent eradication when detected.13 The test-and-
scope strategy performing a test to detect H. pylori in all patients and endoscopy only in those
who are shown to be infected has been considered useful in clinical practice in some developing
countries which has high prevalence of H. pylori infection such as Asia.
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5. Management of H. pylori infection in FD
Both European (Maastricht IV/ Florence Consensus Report) and Asian consensus reports
endorse H. pylori testing and eradication as a key management strategy for patients with
dyspepsia to produce long-term relief of symptoms. [37,38]
6. Antibiotics use for H. pylori eradication
6.1. Amoxicillin
Amoxicillin is a popular antibiotic for treating H pylori infection because it is inexpensive and
well tolerated, while resistance is rare. [39, 40] Amoxicillin acts by inhibiting the synthesis of
the bacterial cell wall and can act locally when delivered into the gastric lumen and systemi‐
cally once absorbed into the bloodstream. Amoxicillin is pH-dependent; its bactericidal activity
increases as the pH rises. As a single agent antibiotic use is not capable of curing H. pylori
infection, amoxicillin must be combined with other antibiotics such as clarithromycin and
metronidazole. [4]
6.2. Clarithromycin
Clarithromycin, a 14-membered ring macrolide antibiotic, is a derivative of erythromycin,
sharing a close spectrum and clinical application. Clarithromycin is one of the most acid-stable
macrolide with a low minimum inhibitory concentration (MIC) for H. pylori treatment. The
antimicrobial activity results from its binding to bacterial ribosomes and disrupting bacterial
proteinsynthesis. [4] Currently, Clarithromycin resistance is increasing and resulting in a
marked reduction in treatment success. [4, 8, 41] Increasing the clarithromycin dosage does
not overcome the problem of resistance. This antibiotic frequently causes a bitter taste that
causes some patients will stop treatment.
6.3. Metronidazole
Metronidazole is a nitroimidazole group, which is toxic to microaerophilic organisms.
Metronidazole is secreted into gastric juice and saliva, and is active after absorption with a
half-life of 8 to 12 hours. [4] Metronidazoleis is a pH-independent. [42] After entry into the
bacterial cell, metronidazole changes into a toxic form that alters the bacterial enzymes
required for transformation. Unlike clarithromycin, metronidazole resistance can be overcome
by increasing the dosage. The side effects of short-term use of metronidazole include interac‐
tions with alcohol (disulfiram like effect) and gastrointestinal symptoms such as nausea and
vomiting. [4]
6.4. Tetracycline
Tetracycline, a derivative of polycyclic naphtacenecarboxamides, is a fine anti–H. pylori
antimicrobial because it is inexpensive and pH-independent. [4] Tetracycline inhibits bacterial
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protein synthesis and seems to act luminal or locally. [43] The site of action of tetracycline is
the bacterial ribosome, resulting in the interruption of protein biosynthesis. This antibiotic
should not be given to pregnant women or children because it causes permanent staining of
developing teeth. [4]
6.5. Fluoroquinolones
Fluoroquinolones have been used more popularly for H pylori treatment. These drugs block
DNA gyrase and DNA synthesis  in the organism. Resistance to fluoroquinolones devel‐
ops rapidly, so that prior use of these medications is associated with a significant rate of
resistance. [4]
6.6. Furazolidone
Furazolidone is a monoamine oxidase inhibitor with widely antibacterial activity based on
interference with bacterial enzymes. This antibiotic has proven to be an effective part of
triple therapy while the development of resistance is rare. Furazolidone is an underused
antimicrobial. [44]
6.7. Rifabutin
Rifabutin is a semisynthetic ansamycin antibiotic with low MIC level for H pylori infection.
This antibiotic is becoming more common and primarily used in combination with PPI and
amoxicillin. [4] Rifabutin-based triple therapy for 10 days has been tested as salvage therapy
and found to have high eradication rate of over 80%. Ritabutin can have cross-resistance with
antimycobacterium. [8]
6.8. Other antimicrobial agent
Bismuth compounds are topically active pH-independent antimicrobial drugs that disrupt the
integrity of bacterial cell walls. Bismuth is directly bactericidal, even though its MIC is high
for H pylori. Bismuth is available in two forms (bismuth subsalicylate and bismuth subcitrate),
which have equivalent effect as anti–H pylori therapy. H pylori resistance has not been reported
for this agent. [4]
Regimens available
In recent years, the efficacy of legacy triple therapy for H. pylori eradication has declined
worldwide to an unacceptable level. The average success rate of triple therapy has also
declined to about 70%. [4, 8, 41] Bismuth-based quadruple therapy containing metronidazole
is more effective than triple therapy with overall eradication rate of 83% and the eradication
rate is higher in metronidazole sensitive group than those of the resistant group. [45] A recent
study from Thailand demonstrated that a ten-day sequential therapy is highly effective for H.
pylori infection with eradication rate of 95% but its efficacy affected by clarithromycin resist‐
ance. [41] A study from concomitant therapy evaluated and compared the efficacy of 10-day
and 5-day therapy for H. pylori eradication using PPI with three antibiotics and found that 10-
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day regimen is highly effective with eradication rate of 96% and the 5-day regimen yielded
eradication rate of 88%. [46] The available treatment regimens was summarized in table 1. [4]
Legacy therapies
Triple therapy: A PPI plus amoxicillin, 1 g , plus clarithromycin, 500 mg, or metronidazole/tinidazole, 500 mg, twice a
day for 14 days
Quadruple therapy: Bismuth, metronidazole, 500 mg, tetracycline, 500 mg, three times a day plus a PPI twice a day for
14 days
Concomitant triple therapies
A PPI plus amoxicillin, 1 g, plus clarithromycin, 500 mg, and metronidazole/tinidazole, 500 mg, twice a day for 14 days
Sequential therapy
A PPI plus 1 g amoxicillin, twice a day for 5 days. On day 6 stop amoxicillin and add clarithromycin, 250 or 500 mg and
metronidazole/tinidazole, 500 mg, twice a day to complete the 10-day course.
Table 1. Treatment regimens for Helicobacter pylori infections4
There are many factors that could influence the eradication rate of H. pylori. Compliance is a
major concern and how to make the regimen conveniently used by all patients is important.
Impact of drug metabolism and CYP2C19 on eradication rate is a new point of concern and
needs further research to elucidate this question. The choice of a second-line therapy depends
on local antibiotic resistance pattern, previous treatment, drug availability and cost. Second-
line salvage therapy after primary therapy failure, levofloxacin based triple therapy resulted
in eradication rate of over 80% in patients after failed triple therapy. The accumulation
eradication rate after first-line and second-line therapy becomes nearly 90%. This regimen is
convenient and well-tolerated but antibiotic resistance to levofloxacin needs to be monitored.
Rifabutin-based triple therapy for 10 days has been tested as salvage therapy and found to
have high eradication rate of over 80%. Ritabutin can have cross-resistance with antimyco‐
bacterium. Furazotidone can also be used as salvage therapy but the use is limited by its
availability. The summarized efficacy of H. pylori treatment regimens is: [8]
• Triple therapy containing PPI plus amoxicillin and clarithromycin or metronidazole has
limited efficacy for H. pylori eradication with expected eradication rate of 70%.
• Sequential therapy and concomitant therapy yield high eradication rate of over 90% and
could be used as first - line therapy.
• Bismuth based quadruple therapy could be used as alternative first - line therapy with high
eradication rate.
• Levofloxacin based- triple therapy and concomitant therapy can be used as a second line
salvage therapy after failed first - line therapy.
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